Clinicopathologic features and treatment outcome of non-Hodgkin lymphoma of the breast - a review of 42 primary and secondary cases in Taiwanese patients

被引:20
作者
Lin, Yu-Chin [1 ,2 ]
Tsai, Chung-Hsin [3 ]
Wu, Jia-Shing [4 ]
Huang, Chiun-Sheng [5 ]
Kuo, Sung-Hsin [1 ,6 ,7 ,8 ]
Lin, Chung-Wu [9 ]
Cheng, Ann-Lii [1 ,6 ,7 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 100, Taiwan
[2] Far Eastern Mem Hosp, Dept Internal Med, Div Hematol & Oncol, Taipei, Taiwan
[3] Mackay Mem Hosp, Dept Surg, Taipei, Taiwan
[4] Sun Yat Sen Canc Ctr, Koo Fdn, Dept Radiat Oncol, Taipei, Taiwan
[5] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan
[7] Natl Taiwan Univ, Coll Med, Canc Res Ctr, Taipei, Taiwan
[8] Natl Taiwan Univ Hosp, Dept Oncol, Yunlin, Taiwan
[9] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan
关键词
Breast lymphoma; extranodal lymphoma; prognosis; young age; MALIGNANT-LYMPHOMA; CLASSIFICATION; PROGNOSIS;
D O I
10.1080/10428190902777475
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast lymphoma is a rare form of non-Hodgkin lymphoma (NHL). However, its clinicopathologic features, treatment, patterns of failure and prognosis remains unclear. We reviewed the clinicopathologic features, treatment variables, failure patterns and the clinical outcome of all cases of breast NHL diagnosed in three institutions in Taiwan between 1984 and 2006. The diagnosis, based on the criteria proposed by Wiseman and Liao, was primary breast lymphoma (PBL) in 23 patients and secondary breast lymphoma (SBL) in 19. Diffuse large B-cell lymphoma was the predominant histological type of both. Among patients with PBL, 18 received chemotherapy and radiotherapy, 3 received chemotherapy alone and 2 received radiotherapy alone. In contrast, all 19 patients with SBL received chemotherapy alone. At a median follow-up of 4.4 years, patients with PBL had a significantly better 5-year event-free survival and overall survival. The contralateral breast was the predominant site of recurrence for patients with PBL. In multivariate analyses, young age and stage IIE disease were significantly associated with poorer prognosis of PBL. Our results indicate combined modality treatment results in a favourable outcome for patients with PBL. Further investigation of underlying mechanisms of young age- and stage IIE disease-related poor prognosis in patients with PBL is needed.
引用
收藏
页码:918 / 924
页数:7
相关论文
共 27 条
[1]   Primary breast lymphoma:: Results of a controlled clinical trial [J].
Avilés, A ;
Delgado, SN ;
Nambo, MJ ;
Neri, N ;
Murillo, E ;
Cleto, S .
ONCOLOGY, 2005, 69 (03) :256-260
[2]  
Cabras MG, 2004, HAEMATOLOGICA, V89, P1527
[3]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[4]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[5]   Lymphomas of the breast - Primary and secondary involvement [J].
Domchek, SM ;
Hecht, JL ;
Fleming, MD ;
Pinkus, GS ;
Canellos, GP .
CANCER, 2002, 94 (01) :6-13
[6]  
FREEMAN C, 1972, CANCER, V29, P252, DOI 10.1002/1097-0142(197201)29:1<252::AID-CNCR2820290138>3.0.CO
[7]  
2-#
[8]   Non-Hodgkin lymphoma of the breast [J].
Ganjoo, Kristen ;
Advani, Ranjana ;
Mariappan, M. Rajan ;
McMillan, Alex ;
Horning, Sandra .
CANCER, 2007, 110 (01) :25-30
[9]   Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern cooperative oncology group study 1484 [J].
Horning, SJ ;
Weller, E ;
Kim, KM ;
Earle, JD ;
O'Connell, MJ ;
Habermann, TM ;
Glick, JH .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) :3032-3038
[10]  
HUGH JC, 1990, CANCER-AM CANCER SOC, V66, P2602, DOI 10.1002/1097-0142(19901215)66:12<2602::AID-CNCR2820661224>3.0.CO